Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation
2011

Measuring HLA Class I in Kidney Cancer

Sample size: 47 publication Evidence: moderate

Author Information

Author(s): Juliane S Stickel, Natalie Stickel, Jörg Hennenlotter, Karin Klingel, Arnulf Stenzl, Hans-Georg Rammensee, Stefan Stevanović

Primary Institution: University of Tübingen, Germany

Hypothesis

The study aims to directly compare HLA class I molecule levels in renal cell carcinoma tissues versus normal kidney tissues and metastases.

Conclusion

The study found that HLA class I levels are significantly higher in primary tumors and metastases compared to normal kidney tissue, suggesting potential for improved immunotherapy strategies.

Supporting Evidence

  • HLA class I levels were significantly higher in tumor tissues compared to normal kidney tissues.
  • Distant metastases showed higher HLA class I levels than local lymph node metastases.
  • The study used a reliable method for direct quantification of HLA class I molecules.

Takeaway

This study looked at how much of a specific protein, HLA class I, is found in kidney cancer compared to normal kidney tissue, and found more of it in the cancer tissues.

Methodology

The study used Edman degradation to quantify HLA class I molecules from tissue samples of renal cell carcinoma, normal kidney, and metastases.

Potential Biases

Potential bias due to the presence of immune cells in tumor samples affecting HLA quantification.

Limitations

The study's results cannot be generalized due to the limited sample size and heterogeneity of HLA yields.

Participant Demographics

The study included 47 Caucasian patients with renal cell carcinoma.

Statistical Information

P-Value

p = 0.0062 for tumor vs normal tissue; p = 0.0337 for metastases vs normal tissue

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2490-11-1

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication